Finance

Lists
ZTS:NYSE
Zoetis Inc
US$83.82
+1.02%
(+0.85) 1D
US$83.87
+0.06% (+0.050)
After hours
Closed: ኖቬም 13, 4:01:21 ከሰዓት ጂ ኤም ቲ-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ZTS...
Open
US$83.50
High
US$83.85
Low
US$82.26
Mkt. cap
34.06 ቢ
Avg. vol.
4.50 ሚ
Volume
3.15 ሚ
Dividend
2.53%
Quarterly dividend
US$0.53
Ex-dividend date
30 ኦክቶ 2026
P/E ratio
14.24
52-wk high
US$132.49
52-wk low
US$68.77
EPS
US$5.89
Beta
0.67
Shares outstanding
406.32 ሚ
No. of employees
14 ሺ
Open
US$83.50
High
US$83.85
Low
US$82.26
Mkt. cap
34.06 ቢ
Avg. vol.
4.50 ሚ
Volume
3.15 ሚ
Dividend
2.53%
Quarterly dividend
US$0.53
Ex-dividend date
30 ኦክቶ 2026
P/E ratio
14.24
52-wk high
US$132.49
52-wk low
US$68.77
EPS
US$5.89
Beta
0.67
Shares outstanding
406.32 ሚ
No. of employees
14 ሺ
News stories
From web sources and news partners
Profile
Zoetis Inc., headquartered in Parsippany, New Jersey, is the largest producer of medicine and vaccinations for pets and livestock worldwide. The company's products include antiparasitics, vaccines, products that relieve itch, anti-infectives, products that alleviate pain, animal health diagnostics, as well as hormones, cardiopulmonary, topical and oral hygiene therapeutics, central nervous system drugs, diuretics, antiemetic, euthanasia, and hepato-digestive products. The company has operations in over 50 countries. In 2025, 70% of the company's revenue came from products for pets and 29% of the company's revenues came from products for livestock. In 2025, 54% of the company's revenue came from customers in the United States. Of this revenue, 79% came from products for dogs and cats, 13% came from products for cattle, and 4% came from products for horses. In 2025, 46% of the company's revenue came from international customers. Of this revenue, 53% came from products for dogs and cats, 19% came from products for cattle, 9% came from products for swine, 7% came from products for poultry, and 3% came from products for horses. Wikipedia
About Zoetis Inc
CEOKristin C. Peck
Employees14.5 ሺ
Founded1952
HeadquartersParsippany-Troy Hills, ኒው ጄርዚ, ዩናይትድ ስቴትስ
SectorHealth Care
IndustryPharmaceutical industry
Websitezoetis.com
Analyst ratings
Based on 11 analysts giving stock ratings to ZTS in the past 3 months
Buy
Buy
3
Hold
8
Sell
0
12-month forecast
Based on 11 Wall Street analysts offering 12 month price targets for ZTS in the last 3 months.
Highest
Current US$83.82
US$115.00 (+37.20%)
Average
US$87.00 (+3.79%)
Lowest
US$74.00 (-11.72%)
Analyst
Recommendation
Action
Price target
Projected
Date
David Westenberg
Piper Sandler
Hold
Maintained
US$80.00
-4.6%
11/09/2026
Andrea Alfonso
UBS
Hold
Maintained
US$85.00
+1.4%
11/06/2026
Scott Schoenhaus
KeyBanc
Hold
Maintained
-
-
11/06/2026
Jonathan Block
Stifel Nicolaus
Hold
Maintained
US$85.00
+1.4%
11/05/2026
Erin Wright
Morgan Stanley
Buy
Maintained
US$82.00
-2.2%
10/30/2026
Keith Devas
Jefferies
Hold
Downgraded
US$83.00
-1%
10/20/2026
Chris Schott
J.P. Morgan
Buy
Maintained
US$115.00
+37.2%
10/16/2026
Matthew Dellatorre
Goldman Sachs
Hold
Initiated
US$74.00
-11.7%
10/16/2026
Daniel Clark
Leerink Partners
Hold
Reiterated
-
-
10/01/2026
Steve Scala
TD Cowen
Buy
Reiterated
US$94.00
+12.1%
08/25/2026
Glen Santangelo
Barclays
Hold
Reiterated
US$85.00
+1.4%
08/17/2026
Daniel Grosslight
Citi
Buy
Maintained
US$96.00
+14.5%
08/11/2026
Ryan Daniels
William Blair
Hold
Downgraded
-
-
08/06/2026
Brandon Vazquez
William Blair
Hold
Downgraded
-
-
08/08/2026
Michael Ryskin
Bank of America Securities
Hold
Maintained
-
-
07/28/2026
Sidharth Sahoo
HSBC
Buy
Maintained
US$95.00
+13.3%
07/06/2026
Jasper Hellweg
Argus Research
Hold
Downgraded
-
-
05/26/2026
Thomas DeBourcy
Nephron
Hold
Downgraded
US$131.00
+56.3%
03/05/2026
Mark Massaro
BTIG
Buy
Reiterated
US$160.00
+90.9%
02/26/2026
Last report
5 ኖቬም 2026
Fiscal period
Q3 2026
US$1.75 / US$1.51
+15.81%beat
Revenue / Est. (USD)
2.39 ቢ / 2.30 ቢ
+3.88%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
ዲሴም 2025
ማርች 2026
ጁን 2026
ሴፕቴ 2026
Revenue
2.39 ቢ
2.26 ቢ
2.47 ቢ
2.39 ቢ
Cost of goods sold
711.00 ሚ
640.00 ሚ
670.00 ሚ
696.00 ሚ
Cost of revenue
711.00 ሚ
640.00 ሚ
670.00 ሚ
696.00 ሚ
Research and development expenses
199.00 ሚ
180.00 ሚ
173.00 ሚ
174.00 ሚ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
618.00 ሚ
584.00 ሚ
589.00 ሚ
577.00 ሚ
Operating expense
848.00 ሚ
795.00 ሚ
793.00 ሚ
782.00 ሚ
Total operating expenses
1.56 ቢ
1.44 ቢ
1.46 ቢ
1.48 ቢ
Operating income
828.00 ሚ
827.00 ሚ
1.00 ቢ
913.00 ሚ
Other non operating income
-6.00 ሚ
-1.00 ሚ
-2.00 ሚ
-3.00 ሚ
EBT including unusual items
761.00 ሚ
758.00 ሚ
866.00 ሚ
729.00 ሚ
EBT excluding unusual items
780.00 ሚ
779.00 ሚ
948.00 ሚ
857.00 ሚ
Income tax expense
158.00 ሚ
157.00 ሚ
175.00 ሚ
138.00 ሚ
Effective tax rate
20.76%
20.71%
20.21%
18.93%
Other operating expenses
-
-
-
-
Net income
603.00 ሚ
601.00 ሚ
691.00 ሚ
591.00 ሚ
Net profit margin
25.26%
26.57%
28.00%
24.72%
Earnings per share
1.48
1.53
1.87
1.75
Interest and investment income
25.00 ሚ
21.00 ሚ
16.00 ሚ
17.00 ሚ
Interest expense
-57.00 ሚ
-62.00 ሚ
-61.00 ሚ
-62.00 ሚ
Net interest expenses
-32.00 ሚ
-41.00 ሚ
-45.00 ሚ
-45.00 ሚ
Depreciation and amortization charges
-
-
-
-
EBITDA
903.00 ሚ
946.00 ሚ
1.12 ቢ
1.03 ቢ
Gain or loss from assets sale
-
-6.00 ሚ
-1.00 ሚ
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google መተግበሪያዎች